- Home
- PNI vs NOTV Comparison
PNI vs NOTV Comparison
Compare PNI & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- NOTV
- Stock Information
- Founded
- PNI 2002
- NOTV 1974
- Country
- PNI United States
- NOTV United States
- Employees
- PNI N/A
- NOTV N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- PNI Finance
- NOTV Health Care
- Exchange
- PNI Nasdaq
- NOTV Nasdaq
- Market Cap
- PNI 75.2M
- NOTV 69.4M
- IPO Year
- PNI N/A
- NOTV 1997
- Fundamental
- Price
- PNI $6.76
- NOTV $2.09
- Analyst Decision
- PNI
- NOTV Strong Buy
- Analyst Count
- PNI 0
- NOTV 1
- Target Price
- PNI N/A
- NOTV $5.00
- AVG Volume (30 Days)
- PNI 26.4K
- NOTV 715.2K
- Earning Date
- PNI 01-01-0001
- NOTV 08-07-2025
- Dividend Yield
- PNI 4.76%
- NOTV N/A
- EPS Growth
- PNI N/A
- NOTV N/A
- EPS
- PNI N/A
- NOTV N/A
- Revenue
- PNI N/A
- NOTV $480,402,000.00
- Revenue This Year
- PNI N/A
- NOTV $4.99
- Revenue Next Year
- PNI N/A
- NOTV $5.39
- P/E Ratio
- PNI N/A
- NOTV N/A
- Revenue Growth
- PNI N/A
- NOTV N/A
- 52 Week Low
- PNI $6.03
- NOTV $1.15
- 52 Week High
- PNI $7.89
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- PNI 56.47
- NOTV 48.26
- Support Level
- PNI $6.61
- NOTV $1.66
- Resistance Level
- PNI $6.77
- NOTV $3.19
- Average True Range (ATR)
- PNI 0.06
- NOTV 0.19
- MACD
- PNI 0.01
- NOTV -0.02
- Stochastic Oscillator
- PNI 93.75
- NOTV 61.43
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.